Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsPaul Feuerstadt, MD, FACG, AGAF
Associate Clinical ProfessorAbout
Copy Link
Biography
A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude.
Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.
Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include chronic diarrheal syndromes with a specific focus on Clostridiodes difficile infection, irritable bowel syndrome (IBS) and ischemic diseases of the gut. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. Dr. Feuerstadt founded a website entitled "Everythingcdifficile.com" as an educational resource for patients and providers about this infectious disease. Finally, he is passionate about mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as an Assistant Clinical Professor of Medicine.
His clinical practice is his ultimate passion filling the majority of his work time as he sees a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital.
Appointments
Digestive Diseases
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Montefiore Medical Center-Albert Einstein College of Medicine (2010)
- Categorical Resident
- New York Presbyterian Hospital-Weill Cornell Medical Center (2007)
- MD
- Weill Cornell Medical College (2004)
- BA
- University of Pennsylvania (2000)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-7643-9576
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Kanika Sehgal, MBBS
Treatment Outcome
Publications
2025
Diagnosis and Management of C. difficile.
Kelly C, Feuerstadt P. Diagnosis and Management of C. difficile. The American Journal Of Gastroenterology 2025 PMID: 41247039, DOI: 10.14309/ajg.0000000000003844.Peer-Reviewed Original ResearchConceptsClostridioides difficile infectionFecal microbiota transplantationMicrobiota-based therapiesFulminant Clostridioides difficile infectionManagement of C. difficileCDI diagnosisRecurrent Clostridioides difficile infectionFirst-line therapySpectrum of disease severityTreatment paradigmMicrobiota transplantationTherapeutic approachesC. difficileDiagnostic testsClinical observationsDisease severityTherapyDiagnosisPublished studiesFecal microbiotaFidaxomicinVancomycinTransplantationMetronidazolePatientsIntegrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update
Lee C, Feuerstadt P, Louie T, Bancke L, Guthmueller B, Harvey A, Hoeyer F, Orenstein R, Dubberke E, Khanna S. Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251395566. PMID: 41245385, PMCID: PMC12612505, DOI: 10.1177/17562848251395566.Peer-Reviewed Original ResearchAltmetricConceptsTreatment-emergent adverse eventsStandard-of-careSerious treatment-emergent adverse eventsSafety dataStandard-of-care therapyRecurrent Clostridioides difficile infectionPhase III trialsClostridioides difficile infectionIII trialsFecal microbiotaTreatment courseSafety profileAntibiotic treatmentAdverse eventsClinical trialsPreexisting conditionsRCDITrialsPhase IIInfectionTreatmentMicrobiome and metabolome changes after fecal microbiota, live-jslm, administration are associated with health-related quality of life improvements
Mishra R, Harvey A, Guo A, Tillotson G, Feuerstadt P, Khanna S, Shannon W, Blount K. Microbiome and metabolome changes after fecal microbiota, live-jslm, administration are associated with health-related quality of life improvements. Anaerobe 2025, 96: 103006. PMID: 41115624, DOI: 10.1016/j.anaerobe.2025.103006.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsMetabolomic changesGut microbiomeHealth-related qualityFecal microbiotaGut-microbiome-brain axisPlacebo-controlled clinical trialRecurrent C. difficile infectionHRQoL scoresMicrobiota-gut-brain axisRecurrent Clostridium difficile infectionMicrobiota-gut-brainMicrobiome-brain axisHealth-related quality of life improvementMulti-omics dataClostridium difficile infectionC. difficile infectionCentral nervous system functionMental domain scoresTreatment respondersHealth-related quality of life questionnaireQuality of life improvementBile acid compositionQuality of Life QuestionnaireHealth-related quality of lifeFecal microbiomeS337 Explainable Machine Learning Identifies Predictors of Mortality and Colectomy in Colon Ischemia Using SHAPley Additive Explanations (SHAP) and Xtreme Gradient Boosting (XGBoost)
Patel S, Brandt L, Vaid A, Soroush A, Sehgal K, Eze I, Chaar A, Rizwan R, John S, Muniraj T, Feuerstadt P. S337 Explainable Machine Learning Identifies Predictors of Mortality and Colectomy in Colon Ischemia Using SHAPley Additive Explanations (SHAP) and Xtreme Gradient Boosting (XGBoost). The American Journal Of Gastroenterology 2025, 120: s72-s72. DOI: 10.14309/01.ajg.0001128808.20458.9c.Peer-Reviewed Original ResearchConceptsS1857 Heterogeneity in Randomized Controlled Trials Considering Fecal Microbiota Transplantation to Treat Ulcerative Colitis
Sehgal K, Grimshaw A, Patel S, Feuerstadt P. S1857 Heterogeneity in Randomized Controlled Trials Considering Fecal Microbiota Transplantation to Treat Ulcerative Colitis. The American Journal Of Gastroenterology 2025, 120: s399-s399. DOI: 10.14309/01.ajg.0001134888.85891.d8.Peer-Reviewed Original ResearchS2048 Significant and Durable Microbiome Restoration in a Phase 3 Trial of Fecal Microbiota, Live-JSLM for Recurrent Clostridioides difficile Infection When Administered by Colonoscopy
Khanna S, Feuerstadt P, Van Handel D, Blount K, Ward T, Adamowicz B. S2048 Significant and Durable Microbiome Restoration in a Phase 3 Trial of Fecal Microbiota, Live-JSLM for Recurrent Clostridioides difficile Infection When Administered by Colonoscopy. The American Journal Of Gastroenterology 2025, 120: s440-s440. DOI: 10.14309/01.ajg.0001135652.72435.3d.Peer-Reviewed Original ResearchS2093 Long-Term Safety of Fecal Microbiota, Live-jslm Administered via Colonoscopy to Adults With Recurrent Clostridioides difficile Infection: 6-Month Safety Data From CDI-SCOPE, a Single-Arm, Phase 3b Trial
Khanna S, Feuerstadt P, Awad T, Guthmueller B, Armandi D, Clark B. S2093 Long-Term Safety of Fecal Microbiota, Live-jslm Administered via Colonoscopy to Adults With Recurrent Clostridioides difficile Infection: 6-Month Safety Data From CDI-SCOPE, a Single-Arm, Phase 3b Trial. The American Journal Of Gastroenterology 2025, 120: s449-s450. DOI: 10.14309/01.ajg.0001135832.39482.4e.Peer-Reviewed Original ResearchPrevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA®) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial
Khanna S, Yoho D, Van Handel D, Clark B, Awad T, Guthmueller B, Armandi D, Knapple W, Safdar N, Baggott B, Simon K, Feuerstadt P. Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA®) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251396744. PMID: 41230019, PMCID: PMC12602906, DOI: 10.1177/17562848251396744.Peer-Reviewed Original ResearchConceptsClinical effectsPrevention of recurrent CDIModerate severityTreatment-emergent adverse eventsMonths of follow-upRecurrent Clostridioides difficile infectionPhase IIIb trialClostridioides difficile infectionLong-term safetyCDI recurrenceTreatment failurePrimary endpointSecondary endpointsFecal microbiotaEligible adultsAntibiotic treatmentRight colonAdverse eventsFollow-upTreatment successTEAEsTrial withdrawalColonoscopyRCDIMonthsFecal Microbiota-based therapies compared to Fecal Microbiota Transplantation for Preventing recurrent C. difficile Infection
Nguyen L, Feuerstadt P, Allegretti J, Axelrad J. Fecal Microbiota-based therapies compared to Fecal Microbiota Transplantation for Preventing recurrent C. difficile Infection. Clinical Gastroenterology And Hepatology 2025 PMID: 40930304, PMCID: PMC12433683, DOI: 10.1016/j.cgh.2025.08.029.Peer-Reviewed Original ResearchMulti-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial
Napier B, Allegretti J, Feuerstadt P, Kelly C, Van Hise N, Jäger R, Kassam Z, Reid G. Multi-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial. Nutrients 2025, 17: 2734. PMID: 40944126, PMCID: PMC12430871, DOI: 10.3390/nu17172734.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPlacebo-controlled trialBiological functionsButyrate levelsButyrate-producing speciesGut microbial diversitySystemic inflammationFecal microbiome compositionFecal butyrate levelsMicrobiome-derived metabolitesUrolithin AButyrate producersAlpha diversityMicrobial diversityBeneficial microbesPrecursor metabolismProbiotic strainsButyrate productionMicrobiome compositionHealthy adultsBaseline day 0Fecal butyrateEnd-of-studyPlacebo-ControlledProbiotic supplementationSerum CRP
News
Copy Link
News
- November 06, 2025Source: HCPLive
Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD
- February 18, 2025
Voluntary Faculty Awards Honor Outstanding Educators
- August 29, 2024Source: LiveScience.com
For C. diff, antibiotic resistance comes at a cost
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)